Navigation Links
HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
Date:12/2/2010

FRAMINGHAM, Mass. and SYDNEY, Dec. 2, 2010 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Canaccord Genuity Cardio/Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time).  The conference is being held December 7-8, 2010 at the Nikko Hotel in San Francisco.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for a period of 15 days.

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.For further information:Christopher TaylorHeartWare International, Inc.Email: ctaylor@heartwareinc.comPhone: +1 508 739 0864
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and PUNE, India , January 18, 2017 ... Market Research, titled, "Breast Imaging Technologies Market by Type: Global ... breast imaging technologies market size was valued at $2,544 million ... 2022, growing at a CAGR of 8.4% from 2016 to ... Europe together accounted for over three-fourths market share ...
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  Dermata ... innovative products to treat a variety of dermatological ... lead compound DMT210, in a Phase 2 acne ... developed to downregulate the proinflammatory cytokines in the ... in acne rosacea. This clinical ...
Breaking Medicine Technology:
(Date:1/19/2017)... San Mateo, CA (PRWEB) , ... January 19, ... ... now being taken in the 2017 Spring Create Real Impact contest from Impact ... through March 17 at http://www.createrealimpact.com . , Educational grants totaling $15,000 ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... board member of the American Osteopathic College of Proctology) announced today the ... removal throughout Southern California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles ...
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn facts ... doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common conditions ... this infographic to explain the seven types of hyperhidrosis. This visual creates awareness ...
(Date:1/18/2017)... ... 2017 , ... A Palm Beach doctor plans to run the 2017 London ... provides free surgery to poor children suffering from cleft lip and cleft palate. , ... to support the efforts of the American Heart Association and the Leukemia and Lymphoma ...
Breaking Medicine News(10 mins):